Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-analysis

Clinical Lung Cancer

Volumn 12, Issue 6, 2011, Pages 393-401

  Roth, Joshua A ^a   Carlson, Josh J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ERCC1

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE ASSOCIATION; ETHNICITY; HUMAN; LUNG NON SMALL CELL CANCER; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 80155141268     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.04.005     Document Type: Article

References (43)

1. American Cancer Society Cancer Facts and Figures 2010 2010 American Cancer Society Atlanta, GA
2. NICE ERG report erlotinib for the treatment of relapsed non-small cell lung cancer 2006 The National Institute for Health and Clinical Excellence Liverpool, England
3. W.N. William, H.Y. Lin, and J. Lee Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology, and end results data Chest 136 2009 701 709
4. H.A. Burris Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs Oncogene 28 2009 S4 S13
5. A.G. Pallis, L. Serfass, and R. Dziadziuszko Targeted therapies in the treatment of advanced/metastatic NSCLC Eur J Cancer 45 2009 2473 2487
6. C.G. Azzoli, S. Baker, and S. Temin [in Chinese] American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer 13 2010 171 189
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. V.1. 2011.
8. D. Mu, D.S. Hsu, and A. Sancar Reaction mechanism of human DNA repair excision nuclease J Biol Chem 271 1996 8285 8294 (Pubitemid 26108661)
9. A. Sancar Mechanisms of DNA excision repair Science 266 1994 1954 1956
10. D.B. Zamble, D. Mu, and J.T. Reardon Repair of cisplatinDNA adducts by the mammalian excision nuclease Biochemistry 35 1996 10004 10013 (Pubitemid 26269915)
11. S. Ren, S. Zhou, and L. Zhang High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients Cancer Invest 28 2010 1078 1083
12. C. Su, S. Zhou, and L. Zhang ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer Med Oncol 2010 [Epub ahead of print]
13. X. Wang, J. Zhao, and L. Yang Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer Med Oncol 27 2010 484 490
14. S. Ikeda, K. Takabe, and K. Suzuki Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer Pathol Int 59 2009 863 867
15. H.W. Lee, Y.W. Choi, and J.H. Han Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy Lung Cancer 65 2009 377 382
16. R.V. Lord, J. Brabender, and D. Gandara Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2002 2286 2291 (Pubitemid 34753602)
17. S. Ota, G. Ishii, and K. Goto Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Lung Cancer 64 2009 98 104
18. R. Booton, T. Ward, and L. Ashcroft ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer J Thorac Oncol 2 2007 902 906 (Pubitemid 47511592)
19. B. Holm, A. Mellemgaard, and T. Skov Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine J Clin Oncol 27 2009 4254 4259
20. X.Q. Li, J. Li, and S.B. Shi Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy Int J Biol Markers 24 2009 230 237
21. A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sorensen ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial Ann Oncol 21 2010 1817 1824
22. J. Bellmunt, L. Paz-Ares, and M. Ceullo Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Ann Oncol 18 2007 522 528 (Pubitemid 46359633)
23. I.G. Hwang, Jang Jang, and J.H. Do Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients Cancer Chemother Pharmacol 2011 [Epub ahead of print]
24. S.K. Maithel, I. Coban, and P.J. Kneuertz Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection Ann Surg Oncol 2011 [Epub ahead of print]
25. S.H. Kim, H.C. Kwon, and S.Y. Oh Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer Am J Clin Oncol 32 2009 38 43
26. K.D. Steffenson, M. Waldstrom, and A. Jakobsen The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer Int J Gynecol Cancer 19 2009 820 825
27. M. Cobo, D. Isla, and B. Massuti Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer J Clin Oncol 25 2007 2747 2754 (Pubitemid 47123183)
28. P.A. Bunn, R. Dziadziuszko, and M. Varella-Garcia Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy Clin Cancer Res 12 2006 3652 3656 (Pubitemid 44000246)
29. J.J. Carlson, L.P. Garrison, and S.D. Ramsey Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis J Cancer Res Clin Oncol 135 2009 1483 1493
30. C.N. Oldenhuis, S.F. Oosting, and J.A. Gietema Prognostic versus predictive value of biomarkers in oncology Eur J Cancer 44 2008 946 953
31. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 11 2009 66 73
32. M. Buyse, S. Michiels, and D.J. Sargen Integrating biomarkers in clinical trials Expert Rev Mol Diagn 11 2011 171 182
33. S. Van Schaeybroeck, W.L. Allen, and R.C. Turkington Implementing prognostic and predictive biomarkers in CRC clinical trials Nat Rev Clin Oncol 8 2011 222 232
34. S. Rizzo, G. Bronte, and D. Fanale Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 36 suppl 3 2010 S56 S61
35. D.R. Gandara, T. Kawaguchi, and J. Crowley Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics J Clin Oncol 27 2009 3540 3546
36. A. Vilmar, and J.B. Sorenesen Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature Lung Cancer 64 2009 131 139
37. M.J. Ahn, J. Lee, and Y.H. Park Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era J Thorac Oncol 5 2010 1185 1196
38. S.H. Ou, A. Ziogas, and J.A. Zell Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status J Thorac Oncol 4 2009 1083 1093
39. D.R. Gandara, P. Grimminger, and P.C. Mack Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer J Thorac Oncol 5 2010 1933 1938
40. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991 (Pubitemid 44343542)
41. S. Chen, J. Zhang, and R. Wang The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis Lung Cancer 70 2010 63 70
42. S. Michiels, P. Piedbois, and S. Burdett Meta-analysis when only the median survival times are known: a comparison with individual patient data results Int J Technol Assess Health Care 21 2005 119 125 (Pubitemid 40229377)
43. J.P. Higgins, S.G. Thompson, and J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 2003 557 560 (Pubitemid 37088507)